QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：中南大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文 JAMA Oncology, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui*;  Li, Kai*;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03 anlotinib  non-small-cell lung carcinoma   Use of an Osteoblast Overload Damage Model to Probe the Effect of Icariin on the Proliferation, Differentiation and Mineralization of MC3T3-E1 Cells through the Wnt/beta-Catenin Signalling Pathway. 期刊论文 Cellular Physiology and Biochemistry, 2017, 卷号: 41, 期号: 4, 页码: 1605-1615 作者:  Liu, Yingjie;  Huang, Lulu;  Hao, Baohui;  Li, Hao;  Zhu, Shuanglong 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/03 Icariin  MC3T3-E1  Overload  Wnt/beta-catenin   Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer 期刊论文 BMC Cancer, 2016, 卷号: 16, 期号: 1, 页码: 265 作者:  Sun, Yan*;  Cheng, Ying;  Hao, Xuezhi;  Wang, Jie;  Hu, Chengping 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03 Amrubicin  Chinese  Cisplatin  ED-SCLC  Etoposide  Randomized clinical trial   BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. 期刊论文 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 卷号: 33, 期号: 19, 页码: 2197-U108 作者:  Zhou, Caicun*;  Wu, Yi-Long;  Chen, Gongyan;  Liu, Xiaoqing;  Zhu, Yunzhong 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/03